# Lactobacillus helveticus R389

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-helveticus-r389
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** L. helveticus R389, Lactobacillus helveticus strain R389, LH R389, L. helveticus R-389

## Overview

Lactobacillus helveticus R389 is a [probiotic](/ingredients/condition/gut-health) strain that modulates [immune function](/ingredients/condition/immune-support) by stimulating secretory IgA production and expanding CD4+ T-cell populations in gut-associated lymphoid tissue. Its primary mechanisms involve upregulating calcineurin signaling and calcium channel expression to enhance mucosal barrier immunity and, in preliminary animal models, suppress tumor growth.

## Health Benefits

• Enhanced [immune function](/ingredients/condition/immune-support) through increased IgA+ and CD4+ cells (preliminary mouse evidence, PMID: 16164041)
• Anti-tumor activity with delayed breast cancer growth in mice (preliminary evidence, PMID: 16831211)
• Improved gut immunity via upregulation of calcineurin and calcium channels (preliminary mouse evidence, PMID: 17825099)
• Protection against Salmonella infection in animal models (preliminary evidence, PMID: 17336831)
• Modulation of [inflammatory](/ingredients/condition/inflammation) cytokines with increased IL-10 and reduced IL-6 (preliminary mouse evidence only)

## Mechanism of Action

Lactobacillus helveticus R389 activates calcineurin, a calcium-dependent phosphatase, which dephosphorylates NFAT transcription factors and promotes IgA class-switching in gut-associated lymphoid tissue. Simultaneously, the strain upregulates epithelial calcium channels, increasing intracellular calcium flux that supports [T-cell](/ingredients/condition/immune-support) activation and CD4+ lymphocyte proliferation. In murine breast cancer models, the strain is believed to modulate immune surveillance pathways, potentially through enhanced NK-cell and cytotoxic T-lymphocyte activity, slowing tumor progression.

## Clinical Summary

Current evidence for Lactobacillus helveticus R389 is limited exclusively to preclinical mouse studies, with no published human clinical trials as of the available literature. In murine experiments (PMID: 16164041), oral administration significantly increased intestinal IgA+ cells and circulating CD4+ T-cells compared to controls, suggesting [immunomodulatory](/ingredients/condition/immune-support) activity. A separate mouse study (PMID: 16831211) demonstrated delayed breast tumor growth following supplementation, though effect sizes and dosing protocols varied across experiments. Until randomized controlled trials in humans are conducted, all benefit claims remain preliminary and cannot be extrapolated to human populations with confidence.

## Nutritional Profile

Lactobacillus helveticus R389 is a [probiotic](/ingredients/condition/gut-health) bacterial strain, not a conventional nutrient source, so macronutrient/micronutrient profiling is not directly applicable in traditional terms. As a live bacterial culture, it contributes negligible caloric value. Bioactive compounds of relevance include cell wall-associated peptidoglycans and lipoteichoic acids that interact with host Toll-like receptors (TLR2), exopolysaccharides that modulate mucosal immunity, and secreted metabolites including short-chain fatty acids (primarily lactic acid) and bacteriocins. The strain produces bioactive peptides during milk fermentation (e.g., casein-derived tripeptides IPP and VPP, though strain-specific yield varies). It also contributes to local synthesis of B-vitamins (folate, B12 precursors) in the gut microenvironment. Bioavailability of its effects is contingent on viable cell delivery — survival through gastric acid is moderate for this species; enteric encapsulation improves colonic delivery. [Immunomodulatory](/ingredients/condition/immune-support) activity is mediated via IgA+ and CD4+ T-cell stimulation documented at doses used in murine models (specific CFU doses not fully translated to human equivalents). Calcium-channel and calcineurin upregulation effects suggest indirect enhancement of mineral signaling pathways rather than direct mineral delivery.

## Dosage & Preparation

Mouse studies used 0.2 ml of fermented milk supernatant or viable cells at 10^8 CFU/ml administered orally for 7-day cycles. No human dosage data exists. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lactobacillus helveticus R389 has not been evaluated in human safety trials, so a formal adverse event profile has not been established. As a live bacterial strain, it carries a theoretical risk of bacteremia or systemic infection in immunocompromised individuals, those with central venous catheters, or patients recovering from gastrointestinal surgery. Potential interactions with immunosuppressant drugs such as cyclosporine or tacrolimus are plausible given the strain's demonstrated calcineurin-modulating activity, though no direct interaction data exist. Pregnant or breastfeeding individuals should avoid use due to a complete absence of safety data in these populations.

## Scientific Research

All available research on L. helveticus R389 consists of preclinical mouse studies, with no human clinical trials identified. Key studies include [immune modulation](/ingredients/condition/immune-support) in mammary glands (PMID: 16164041), anti-tumor effects in 4T1 breast cancer models (PMID: 16831211), enhanced protection against Salmonella (PMID: 17336831), and gut immunity improvements (PMID: 17825099).

## Historical & Cultural Context

No evidence of traditional use was found in the research. L. helveticus R389 is a modern research strain selected specifically for scientific studies on fermented milk [immunomodulat](/ingredients/condition/immune-support)ion, with no documented historical or cultural applications.

## Synergistic Combinations

Lactobacillus helveticus R389 pairs well with (1) Bifidobacterium longum, which complements its IgA-stimulating effects through distinct TLR9-mediated pathways, creating additive mucosal immune reinforcement; (2) [Prebiotic](/ingredients/condition/gut-health) inulin or fructooligosaccharides (FOS), which selectively feed Lactobacillus species, significantly improving colonization persistence and metabolite output including lactic acid and SCFA production; (3) Vitamin D3 (cholecalciferol), whose [immunomodulatory](/ingredients/condition/immune-support) effects on CD4+ T-cell differentiation directly complement R389's observed upregulation of the same cell population, acting through convergent but non-redundant pathways (VDR signaling vs. direct microbial stimulation); and (4) Lactoferrin, which enhances the anti-pathogenic effects of R389 against organisms like Salmonella through complementary mechanisms — lactoferrin sequesters iron required for pathogen growth while R389 competes for mucosal adhesion sites, creating a dual-barrier effect.

## Frequently Asked Questions

### What does Lactobacillus helveticus R389 do for the immune system?

In mouse studies, Lactobacillus helveticus R389 increased IgA-secreting cells and CD4+ T-lymphocytes in gut-associated lymphoid tissue, suggesting enhanced mucosal immune defense. It achieves this partly by activating calcineurin and upregulating calcium channels, which promote immune cell signaling. No human data currently confirm these effects.

### Can Lactobacillus helveticus R389 help fight cancer?

Preliminary mouse research (PMID: 16831211) showed that oral administration of L. helveticus R389 delayed breast tumor growth compared to untreated controls, likely through immune surveillance enhancement. However, these findings come exclusively from animal models, and no human oncology trials have been conducted. It should not be considered a cancer treatment or prevention strategy based on current evidence.

### How is Lactobacillus helveticus R389 different from other Lactobacillus helveticus strains?

Lactobacillus helveticus R389 is a specific strain distinguished by its documented ability to upregulate calcineurin activity and intestinal calcium channel expression, effects not necessarily shared by other L. helveticus strains such as R0052. Probiotic benefits are highly strain-specific, meaning research on one strain cannot be applied to another even within the same species. Always verify that research cited for L. helveticus pertains specifically to the R389 designation.

### What is the studied dosage of Lactobacillus helveticus R389?

Published mouse studies have not standardized a dosage that translates directly to human supplementation recommendations, and no human dose-finding trials exist for L. helveticus R389. Murine protocols typically involve daily oral gavage of bacterial suspensions quantified in colony-forming units (CFUs), but these amounts are not directly convertible to human doses without allometric scaling and clinical validation. Any commercially available products listing this strain should be evaluated critically, as efficacious human dosing remains undefined.

### Is Lactobacillus helveticus R389 safe for people with weakened immune systems?

Individuals with compromised immune systems, including those undergoing chemotherapy, taking immunosuppressants, or living with HIV, face an elevated theoretical risk when taking any live probiotic strain, including L. helveticus R389. Cases of Lactobacillus bacteremia have been documented with other probiotic strains in immunocompromised patients, and R389 has no human safety data to rule out this risk. Immunocompromised individuals should consult a physician before using any live bacterial supplement.

### Is Lactobacillus helveticus R389 safe during pregnancy and breastfeeding?

Lactobacillus helveticus R389 is generally recognized as safe, as Lactobacillus helveticus is a food-grade probiotic species with a long history of use in dairy products. However, pregnant and breastfeeding women should consult their healthcare provider before starting any new supplement, as clinical safety data specifically for this strain in these populations is limited. Most probiotics are considered low-risk during pregnancy and lactation when sourced from reputable manufacturers with proper quality controls.

### What does the research say about Lactobacillus helveticus R389 for gut health?

Preliminary animal studies demonstrate that Lactobacillus helveticus R389 enhances gut immunity by upregulating calcineurin and calcium channel signaling, which supports intestinal barrier function and immune tolerance. The strain has also shown protective effects against Salmonella infection in animal models, suggesting potential benefits for pathogenic resistance. However, most evidence remains preclinical; human clinical trials are needed to confirm these mechanisms translate to meaningful health outcomes in people.

### Does Lactobacillus helveticus R389 interact with antibiotics or other common medications?

Probiotics like Lactobacillus helveticus R389 may have reduced viability if taken simultaneously with broad-spectrum antibiotics, since antibiotics can kill beneficial bacteria. It is generally recommended to take probiotics at least 2–3 hours apart from antibiotic doses to maximize probiotic survival. Consult with a pharmacist or healthcare provider about timing if you are taking antibiotics, immunosuppressants, or other medications that affect gut microbiota.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*